Suppr超能文献

心力衰竭表型谱中瑞典心力衰竭注册研究中明显的治疗抵抗性高血压。

Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry.

机构信息

BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.

Department of Medicine, Karolinska Institute, Stockholm, Sweden.

出版信息

JACC Heart Fail. 2022 Jun;10(6):380-392. doi: 10.1016/j.jchf.2022.04.006.

Abstract

BACKGROUND

Hypertension is common in patients with heart failure (HF), but less is known about resistant hypertension.

OBJECTIVES

This study sought to investigate apparent treatment-resistant hypertension (aTRH) in patients with HF in the SwedeHF (Swedish Heart Failure Registry), across the spectrum of HF phenotypes (heart failure with reduced ejection fraction [HFrEF], heart failure with mildly reduced ejection fraction [HFmrEF], and heart failure with preserved ejection fraction [HFpEF]).

METHODS

aTRH was defined as systolic blood pressure ≥140 mm Hg (≥135 mm Hg in diabetes) despite treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or sacubitril-valsartan, as well as a calcium-channel blocker and a diuretic; non-treatment-resistant hypertension (TRH) was defined as systolic blood pressure above these thresholds but not on the 3-drug combination; and normal blood pressure was defined as under these thresholds. In each left ventricular ejection fraction (LVEF) category, patient factors associated with aTRH and non-TRH and outcomes (HF hospitalization and cardiovascular death composite, its components, and all-cause death) according to hypertension category were examined.

RESULTS

Among 46,597 patients, aTRH was present in 2,693 (10%), 1,514 (14%), and 1,450 (17%) patients with HFrEF, HFmrEF, and HFpEF, respectively. Older age, obesity, diabetes, and kidney disease were associated with a greater likelihood of aTRH and non-TRH (vs normal blood pressure). Associations were generally similar irrespective of LVEF category. Compared with normal blood pressure, aTRH was associated with a lower adjusted risk of the composite outcome in HFrEF and HFmrEF (HR: 0.79 [95% CI: 0.74-0.85] and HR: 0.86 [95% CI: 0.77-0.96]) but not in HFpEF (HR: 0.93 [95% CI: 0.84-1.04]).

CONCLUSIONS

aTRH was most common in HFpEF and least common in HFrEF. Associated patient characteristics were similar irrespective of LVEF category. aTRH (vs normal blood pressure) was associated with a lower risk of first HF hospitalization or cardiovascular death in HFrEF and HFmrEF but not in HFpEF.

摘要

背景

高血压在心力衰竭(HF)患者中很常见,但对耐药性高血压的了解较少。

目的

本研究旨在调查心力衰竭患者中的显性治疗抵抗性高血压(aTRH),这些患者的心力衰竭表型(射血分数降低的心力衰竭 [HFrEF]、射血分数轻度降低的心力衰竭 [HFmrEF]和射血分数保留的心力衰竭 [HFpEF])各异。

方法

aTRH 的定义为尽管接受了血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂或沙库巴曲缬沙坦治疗,以及钙通道阻滞剂和利尿剂治疗,但收缩压仍≥140mmHg(糖尿病患者≥135mmHg);非治疗抵抗性高血压(TRH)的定义为收缩压高于这些阈值但未接受三联药物治疗;血压正常定义为低于这些阈值。在每个左心室射血分数(LVEF)类别中,根据高血压类别,检查与 aTRH 和非 TRH 相关的患者因素以及与 HF 住院和心血管死亡复合终点相关的结局(其组成部分和全因死亡)。

结果

在 46597 名患者中,HFrEF、HFmrEF 和 HFpEF 患者中分别有 2693 名(10%)、1514 名(14%)和 1450 名(17%)存在 aTRH。年龄较大、肥胖、糖尿病和肾脏疾病与 aTRH 和非 TRH(与血压正常相比)的可能性更大相关。这些关联在 LVEF 类别中通常相似。与血压正常相比,aTRH 与 HFrEF 和 HFmrEF 复合结局的调整后风险较低相关(HR:0.79 [95%CI:0.74-0.85]和 HR:0.86 [95%CI:0.77-0.96]),但在 HFpEF 中则不然(HR:0.93 [95%CI:0.84-1.04])。

结论

aTRH 在 HFpEF 中最常见,在 HFrEF 中最不常见。与 LVEF 类别无关,相关的患者特征相似。与血压正常相比,aTRH 与 HFrEF 和 HFmrEF 中的首次 HF 住院或心血管死亡风险降低相关,但与 HFpEF 中无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验